Daar, E. S., DeJesus, E., Ruane, P., Crofoot, G., Oguchi, G., Creticos, C., Rockstroh, J. K., Molina, J., Koenig, E., Liu, Y., Custodio, J., Andreatta, K., Graham, H., Cheng, A., Martin, H., & Quirk, E. (2018). efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet, 5(7), e347–e356. http://access.bl.uk/ark:/81055/vdc_100066508650.0x000001